SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease.
Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and premature mortality among children and young adults, particularly in low- and middle-income countries. Current management relies on antibiotic …